It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

BofA analyst Jason Gerberry raised the firm’s price target on Jazz Pharmaceuticals (JAZZ ... trading at “highly depressed multiples,” yet offering mid-single digit sales and high-single digit bottom ...

Jefferies raised the firm’s price target on Verona Pharma (VRNA) to $45 from $38 and keeps a Buy rating on the shares. Ohtuvayre reported ...

Mepsevii sales also jumped ... and justifies the increased price target to $95 based on revisions to their financial model. In other recent news, Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc ...

HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...

The raised stock price target to $42 per American ... remains optimistic about continued sales growth and the drug's broad prescription base. Verona Pharma's recent financial performance and ...

On Friday, Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.17 or 2.45% from the prior close of $6.93. The stock opened ...

The raised stock price target to $42 per American Depositary ... Despite the net loss for Q3, the company remains optimistic about continued sales growth and the drug's broad prescription base. Verona ...